← Back to Search

Arm 1 for Brain Metastases

Phase 1
Waitlist Available
Research Sponsored by Life Molecular Imaging SA
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0-75 min
Awards & highlights

Study Summary

The aim of this study is to explore the efficacy of 18F-FSPG in the detection of primary or metastatic brain cancer lesions confirmed by a standard of truth, preferably histology. This is a single center, open labelled, non-randomized study. A total of 30 subjects with brain tumor or brain metastases will be enrolled. All different stages of malignancies will be recruited, including those with different types of pathologies and grades, and newly diagnosed or recurrent disease.

Eligible Conditions
  • Brain Metastases

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0-75 min
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0-75 min for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Location and number of lesions and their location as detected by 18F-FSPG uptake above background in the brain of each study subject following visual inspection of the 18F-FSPG PET/CT scans
Secondary outcome measures
18F-FSPG standardized uptake value (SUV) measured in each detected lesion and in the background (region without lesion).
Determination of FSPG PET/CT image quality based on visual inspection.
Lesion size measured by means of ROIs drawn on (contrast-enhanced) MR or CT.
+3 more

Side effects data

From 2016 Phase 2 trial • 7 Patients • NCT02599194
14%
Elevated blood ammonia
100%
80%
60%
40%
20%
0%
Study treatment Arm
18F-FSPG and 18F-FDG Intragroup Comparision

Trial Design

1Treatment groups
Experimental Treatment
Group I: Arm 1Experimental Treatment1 Intervention
18F-FSPG will be administered to 30 patients with brain tumors or brain metastases.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Florilglutamic acid F-18
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Life Molecular Imaging SALead Sponsor
18 Previous Clinical Trials
1,168 Total Patients Enrolled
Norman Koglin, PhDStudy DirectorLife Molecular Imaging SA

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
PET Imaging of Intracranial Cancers With 18F-FSPG
2014. "PET Imaging of Intracranial Cancers With 18F-FSPG". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02370563.
~2 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top